首頁 > 市場調查報告書 > 醫療設備

體外診斷孤兒藥

市場調查報告書

商品編碼

2126406

罕見疾病基因檢測市場－策略分析與預測（2026-2035）

Rare Disease Genetic Testing Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月10日 | 出版商:

Knowledge Sourcing Intelligence | 英文 174 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計罕見疾病基因檢測市場規模將從 2026 年的 30.2 億美元成長到 2035 年的 79.9 億美元，複合年成長率為 11.4%。

罕見疾病基因檢測市場正經歷重大變革，其驅動力包括精準醫療的模式轉移、全基因測序的廣泛應用，以及人們日益認知到分子層面表徵在罕見遺傳疾病診斷、治療和管理中的關鍵作用。這一市場演變的特點在於，人們逐漸認知到約80%的罕見疾病是由遺傳因素引起的，並且許多患者在獲得明確診斷之前需要經歷漫長的診斷過程。次世代定序、全基因測序、全EXOME定序和人工智慧的融合，使得罕見疾病診斷更加快速、全面且易於取得。早期分子診斷支持個人化治療方案的發展、生育諮詢以及參與疾病特異性臨床試驗，促使醫療系統擴大基因組檢測的覆蓋範圍，以縮短診斷時間並改善臨床管理。隨著疾病修正治療療法和標靶治療普及，精準基因診斷的臨床價值也不斷提升，因為是否治療疾病的決定往往取決於致病性突變的確認。透過對擴充性定序平台、自動化測試工作流程和人工智慧驅動的分析軟體的大量投資，罕見疾病基因檢測正在成為精準醫療和孤兒藥開發的關鍵驅動力。

市場促進因素

精準醫療的擴展是罕見疾病基因檢測市場的主要驅動力。精準醫療正在將基因檢測確立為改善標靶治療選擇和疾病管理的重要工具。由於許多疾病表現出顯著的分子異質性，而傳統診斷方法無法對其進行全面表徵，因此臨床決策越來越依賴基因組資訊。這種日益成長的依賴促使醫療服務提供者在患者照護流程的早期階段納入全面的基因組檢測。同時，製藥公司正在開發以生物標記主導的療法，這些療法需要在治療開始前檢驗的伴隨診斷，從而進一步整合治療和分子診斷。因此，藥物開發和基因組診斷之間的合作正在加強，推動了腫瘤學、罕見疾病和遺傳性疾病領域對先進基因檢測平台的長期需求，並永續地擴大了罕見疾病基因檢測的應用。罕見遺傳疾病負擔的加重也透過對全面定序的需求進一步加速了市場成長。罕見疾病代表著巨大的未滿足臨床需求，因為許多患者在獲得明確診斷之前需要經歷漫長的診斷過程。在醫療保健系統中，新一代定序（NGS）技術正被日益廣泛地應用於提高整體遺傳性疾病的診斷準確性。傳統的診斷流程通常需要依序進行多項檢測，這會導致醫療成本增加和治療決策延誤。為了應對這項挑戰，臨床檢查室正在擴展EXOME和基因測序能力，使其能夠同時評估數千個與疾病相關的基因。產前和生殖篩檢的普及增加了臨床實驗室的檢測數量，並強化了持續的需求。在生殖醫學領域，基因檢測被認為是識別孕前或孕期遺傳疾病風險的關鍵策略。帶因者篩檢、非侵入性產前檢測（NIPT）和胚胎植入前遺傳學檢測（PGT）因其能夠更早提供基因資訊並降低手術風險，在臨床實踐中得到越來越廣泛的應用。 NGS技術的進步降低了操作複雜性並提高了處理能力，使其更易於在臨床環境中使用。與傳統的分子生物學方法相比，NGS能夠以更高的處理能力同時分析多個基因。

市場限制因素

定序基礎設施的高成本、生物資訊學要求以及對專業人員的需求，持續限制著小規模醫院和診斷實驗室對定序技術的應用。先進技術所需的大量資金投入，對小規模機構而言也是一大障礙。儘管越來越多的臨床證據支持基因組醫學，但醫保報銷政策的不一致以及遺傳諮詢服務取得管道的差異，導致檢測利用率仍然很低。不同地區保險覆蓋範圍的差異，為診斷機構帶來了不確定性，也限制了患者的就醫途徑。圍繞著遺傳資訊隱私、意外觀察、知情同意以及長期基因組資料管理等倫理問題，也持續阻礙基因組技術在醫療保健系統中的廣泛應用。遺傳訊息的高度敏感性，也帶來了更高的管治要求。不同司法管轄區法規的複雜性，也給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

市場定義和範圍
罕見疾病概述
罕見疾病基因檢測的發展
主要市場趨勢
實際成果值市場規模分析
市場預測
罕見疾病負擔和未滿足的診斷需求
發病率和盛行率分析
- 罕見病患疾病率
- 確診患者人數
- 未確診疾病患者人數
病人歷程分析
診斷檢測現狀
遺傳諮詢和臨床決策支持

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

定序技術的進步
產品創新
臨床試驗分析
管道分析
人工智慧在罕見疾病突變分析的應用
將數位健康技術應用於罕見疾病診斷

第7章監理情勢

法律規範
核准流程
合規要求

第8章：罕見疾病基因檢測市場：展望分析

分析：按技術平台
分析：透過測試方法
分析：依檢體類型
分析：透過臨床應用
分析：按疾病類別
分析：按最終用戶

第9章：罕見疾病基因檢測市場：細分市場分析

透過技術
- 次世代定序（NGS）
- 全基因測序（WGS）
- 全EXOME定序（WES）
- 目標基因面板
- 其他分子遺傳學檢測技術
按測試類型
- 診斷測試
- 職業篩檢
- 預測性和症狀前檢測
- 產前基因檢測
- 其他
疾病特異性
- 神經病變
- 代謝性疾病
- 心血管疾病
- 血液疾病
- 免疫系統疾病
- 肌肉骨骼疾病
- 其他罕見遺傳疾病
依檢體類型
- 血
- 唾液
- 口腔黏膜拭子
- 組織
- 其他類型的檢體
最終用戶
- 醫院
- 專科診所
- 臨床診斷檢測實驗室
- 其他

第10章：罕見疾病基因檢測市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：罕見疾病基因檢測市場：國家分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
韓國
澳洲
巴西
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
新產品發布

第13章：公司簡介

Illumina, Inc.
F. Hoffmann-La Roche Ltd.
QIAGEN NV
Thermo Fisher Scientific Inc.
Revvity, Inc.
Natera, Inc.
Quest Diagnostics Incorporated
Centogene NV
Blueprint Genetics Oy
Myriad Genetics, Inc.

第14章：罕見疾病基因檢測市場：商業預測分析

第15章：投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009118

The Rare Disease Genetic Testing Market is expected to grow at a CAGR of 11.4% from a market value of USD 3.02 billion in 2026 to USD 7.99 billion in 2035.

The rare disease genetic testing market is undergoing significant transformation driven by the paradigm shift toward precision medicine, the expanding adoption of comprehensive genomic sequencing, and the growing recognition that molecular characterization is essential for diagnosing, treating, and managing rare genetic disorders. The market's evolution is characterized by the understanding that approximately 80% of rare diseases have a genetic origin, and many patients experience prolonged diagnostic journeys before receiving a definitive confirmation. The convergence of next-generation sequencing, whole genome sequencing, whole exome sequencing, and artificial intelligence is enabling faster, more comprehensive, and increasingly accessible rare disease diagnosis. Healthcare systems are expanding access to genomic testing to shorten diagnostic timelines and improve clinical management, as early molecular diagnosis supports personalized treatment planning, reproductive counseling, and enrollment into disease-specific clinical trials. The growing availability of disease-modifying therapies and targeted treatments increases the clinical value of accurate genetic diagnosis because treatment eligibility frequently depends on confirmation of pathogenic variants. The market is witnessing significant investment in scalable sequencing platforms, automated laboratory workflows, and AI-enabled interpretation software, positioning rare disease genetic testing as a critical enabler of precision medicine and orphan drug development.

Market Drivers

The expansion of precision medicine represents the primary driver for the rare disease genetic testing market. Precision medicine establishes genetic testing as a foundational tool for selecting targeted therapies and improving disease management. Clinical decision-making is increasingly relying on genomic information because many diseases exhibit substantial molecular heterogeneity that conventional diagnostic methods cannot fully characterize. This dependence is encouraging healthcare providers to incorporate comprehensive genomic testing earlier in patient care pathways. Pharmaceutical sponsors are simultaneously developing biomarker-driven therapies that require validated companion diagnostics before treatment initiation, reinforcing the integration of therapeutics and molecular diagnostics. The resulting alignment between drug development and genomic diagnostics strengthens long-term demand for advanced genetic testing platforms across oncology, rare diseases, and inherited disorders, resulting in sustained growth in rare disease genetic testing utilization. The growing burden of rare genetic disorders is further accelerating market growth through demand for comprehensive sequencing. Rare diseases represent a significant unmet clinical need because many patients experience prolonged diagnostic journeys before receiving a confirmed diagnosis. Healthcare systems are increasingly implementing NGS technologies to improve diagnostic yield across genetically diverse disorders. Conventional diagnostic algorithms often require multiple sequential investigations, increasing healthcare costs and delaying treatment decisions. Clinical laboratories are responding by expanding exome and genome sequencing capabilities that simultaneously evaluate thousands of disease-associated genes. The expansion of prenatal and reproductive screening is broadening clinical testing volumes and strengthening recurring demand. Reproductive medicine recognizes genetic testing as an important strategy for identifying inherited disease risk before or during pregnancy. Clinical practice is increasingly incorporating carrier screening, NIPT, and PGT because these approaches provide earlier genetic information with reduced procedural risk. Advancements in NGS technologies are improving clinical accessibility through reduced operational complexity and higher throughput. NGS enables simultaneous analysis of multiple genes with higher throughput than conventional molecular methods.

Market Restraints

High sequencing infrastructure costs, bioinformatics requirements, and specialized workforce needs continue limiting adoption among smaller hospitals and diagnostic laboratories. The significant financial investment required for advanced technologies creates barriers for smaller facilities. Variability in reimbursement policies and unequal access to genetic counseling reduce testing utilization despite expanding clinical evidence supporting genomic medicine. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Ethical concerns surrounding genetic privacy, incidental findings, informed consent, and long-term genomic data management continue complicating broader implementation across healthcare systems. The sensitive nature of genetic information creates additional governance requirements. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Product Insights

The technology landscape is characterized by the growing importance of comprehensive genomic sequencing, multi-omics integration, and AI-enabled variant interpretation. NGS enables simultaneous analysis of multiple genes with higher throughput than conventional molecular methods. WGS and WES provide comprehensive genomic characterization. Targeted gene panels support focused analysis of specific disease-associated genes. The segment analysis reveals that neurological disorders represent a significant application area because many neurodevelopmental and neurodegenerative diseases have identifiable genetic causes that influence diagnosis and clinical management. Clinical practice is increasingly incorporating NGS panels and WES because conventional neurological investigations frequently fail to identify underlying molecular abnormalities. Blood remains the predominant sample type because it provides high-quality genomic DNA while integrating efficiently into routine clinical laboratory workflows. Diagnostic testing constitutes the largest test type segment because clinical confirmation of suspected rare diseases remains the primary indication for genetic testing. Clinical diagnostic laboratories constitute the largest end-user segment because they possess specialized sequencing infrastructure, bioinformatics capabilities, and accredited quality systems required for complex genomic analysis. The integration of AI is becoming increasingly important because AI platforms are increasingly assisting laboratories by prioritizing pathogenic variants, integrating literature evidence, and supporting standardized classification workflows.

Competitive and Strategic Outlook

The competitive landscape features established sequencing and diagnostics companies alongside specialized rare disease, genomic, and precision medicine providers. Illumina remains strategically distinct because it has established one of the world's most comprehensive NGS ecosystems spanning sequencing instruments, consumables, software, and genomic analytics, continuing to strengthen market leadership through high-throughput sequencing platforms that support clinical diagnostics, translational research, reproductive health, oncology, and population genomics. Roche differentiates itself through the integration of pharmaceuticals and diagnostics, allowing coordinated development of targeted therapies and companion diagnostics, continuing to expand its molecular diagnostics portfolio across oncology, infectious diseases, and inherited disorders. QIAGEN maintains strategic differentiation through its integrated portfolio of sample preparation technologies, molecular assays, bioinformatics solutions, and companion diagnostic capabilities, supporting laboratories across the entire molecular testing workflow. Thermo Fisher Scientific occupies a strong competitive position because it offers one of the industry's broadest portfolios of sequencing instruments, PCR systems, reagents, laboratory automation technologies, and genomic software. Natera differentiates itself through its focus on cell-free DNA technology and proprietary testing platforms serving oncology, reproductive health, and organ transplantation. Myriad Genetics has established a strong position in hereditary disease testing through extensive expertise in molecular diagnostics, clinical interpretation, and genetic counseling support. Companies are pursuing product portfolio expansion through innovation in NGS platforms, AI-enabled interpretation tools, and companion diagnostic solutions. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for precision medicine and orphan drug development. Recent key developments include The Jackson Laboratory joining the Broad Institute and Boston Children's Hospital to launch the Center for Therapeutic Genetics, a nonprofit effort to develop genetic medicines for rare and ultra-rare diseases. Natera launched Zenith Genomics as a whole-genome sequencing test designed to improve the diagnosis of rare genetic conditions. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The rare disease genetic testing market is positioned for sustained growth driven by the convergence of precision medicine, technological innovation, and orphan drug development. The transition from sequential single-gene testing toward comprehensive genomic sequencing represents a fundamental shift in rare disease management. While challenges related to high costs, reimbursement variability, and ethical considerations persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with rare disease genetic testing evolving into a critical enabler of precision medicine, supporting earlier diagnosis, therapeutic selection, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Rare Disease Genetic Testing Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Rare Disease Overview
3.3 Evolution of Rare Disease Genetic Testing
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Rare Disease Burden & Unmet Diagnostic Needs
3.8 Epidemiology and Prevalence Analysis
- 3.8.1 Rare Disease Prevalence
- 3.8.2 Diagnosed Patient Population
- 3.8.3 Undiagnosed Patient Population
3.9 Patient Journey Analysis
3.10 Diagnostic Testing Landscape
3.11 Genetic Counseling and Clinical Decision Support

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Advances in Sequencing Technologies
6.2 Product Innovation
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 AI Integration in Rare Disease Variant Interpretation
6.6 Digital Health Integration for Rare Disease Diagnosis

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Rare Disease Genetic Testing Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Testing Methodology
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Disease Category
8.6 Analysis by End User

9. Rare Disease Genetic Testing Market Segment Analysis (2021-2035)

9.1 By Technology
- 9.1.1 Next-Generation Sequencing (NGS)
- 9.1.2 Whole Genome Sequencing (WGS)
- 9.1.3 Whole Exome Sequencing (WES)
- 9.1.4 Targeted Gene Panels
- 9.1.5 Other Molecular Genetic Testing Technologies
9.2 By Test Type
- 9.2.1 Diagnostic Testing
- 9.2.2 Carrier Screening
- 9.2.3 Predictive & Presymptomatic Testing
- 9.2.4 Prenatal Genetic Testing
- 9.2.5 Others
9.3 By Disease
- 9.3.1 Neurological Disorders
- 9.3.2 Metabolic Disorders
- 9.3.3 Cardiovascular Disorders
- 9.3.4 Hematological Disorders
- 9.3.5 Immunological Disorders
- 9.3.6 Musculoskeletal Disorders
- 9.3.7 Other Rare Genetic Disorders
9.4 By Sample Type
- 9.4.1 Blood
- 9.4.2 Saliva
- 9.4.3 Buccal Swab
- 9.4.4 Tissue
- 9.4.5 Other Sample Types
9.5 By End User
- 9.5.1 Hospitals
- 9.5.2 Specialty Clinics
- 9.5.3 Clinical Diagnostic Laboratories
- 9.5.4 Others

10. Rare Disease Genetic Testing Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Rare Disease Genetic Testing Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Japan
11.9 China
11.10 India
11.11 South Korea
11.12 Australia
11.13 Brazil
11.14 Saudi Arabia

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 Illumina, Inc.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 F. Hoffmann-La Roche Ltd.
13.3 QIAGEN N.V.
13.4 Thermo Fisher Scientific Inc.
13.5 Revvity, Inc.
13.6 Natera, Inc.
13.7 Quest Diagnostics Incorporated
13.8 Centogene N.V.
13.9 Blueprint Genetics Oy
13.10 Myriad Genetics, Inc.